Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;25(1):173-184.
doi: 10.1007/s12094-022-02924-6. Epub 2022 Aug 22.

Tumor mutational burden and efficacy of chemotherapy in lung cancer

Juan Song #  1   2   3 , Yu Yan #  1   2 , Cuicui Chen #  1   2 , Jiamin Li  1   2 , Ning Ding  1   2 , Nuo Xu  1   2 , Hairong Bao  4 , Xin Zhang  1   2 , Qunying Hong  1   2 , Jian Zhou  1   2 , Yang W Shao  4   5 , Yuanlin Song  1   2   3 , Lin Tong  6   7 , Jie Hu  8   9
Affiliations

Tumor mutational burden and efficacy of chemotherapy in lung cancer

Juan Song et al. Clin Transl Oncol. 2023 Jan.

Abstract

Purpose: TMB is one of the potent biomarkers of response to immune checkpoint blockade. The association between TMB and efficacy of chemotherapy in advanced lung cancer has not been comprehensively explored.

Methods: Ninety lung cancer patients receiving first-line chemotherapy with large panel next-generation sequencing data of pre-treatment tumor tissue were identified. The effect of TMB on PFS of chemotherapy were evaluated in univariate and multivariate analyses.

Results: The median TMB level of lung cancer patients enrolled in this study was 9.4 mutations/Mb, with TMB levels in smokers significantly higher than those in non-smokers. All patients were divided into high TMB and low TMB groups with the cutoff of the median TMB. The patients with low TMB had longer PFS of first-line chemotherapy (median PFS 9.77 vs 6.33 months, HR = 0.523, 95% CI 0.32-0.852, log-rank P = 0.009). Subgroup analysis showed that PFS of chemotherapy favored low TMB than high TMB among subgroups of male, age < 60, NSCLC, adenocarcinoma, stage IV, ECOG PS 0, driver mutation positive, TP53 wild type and patients not receiving bevacizumab. In multivariate analysis, PFS of chemotherapy remained significantly longer in low TMB group (HR = 0.554, p = 0.036). In those patients received immunotherapy upon unsatisfactory chemotherapy, PFS of immunotherapy was much longer in high TMB group (median PFS 32.88 vs 6.62 months, HR = 0.2426, 95% CI 0.06-0.977, log-rank P = 0.04).

Conclusions: TMB level of tumor tissue is a potent biomarker for efficacy of chemotherapy and immunotherapy in lung cancer. It may provide some clues for the decision of treatment strategy.

Keywords: Chemotherapy; Immunotherapy; Lung cancer; Progression-free survival; Tumor mutational burden.

PubMed Disclaimer

References

    1. Hatakeyama K, Nagashima T, Urakami K, Ohshima K, Serizawa M, Ohnami S, et al. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing. Biomed Res. 2018;39(3):159–67. - DOI
    1. Dijkstra KK, Voabil P, Schumacher TN, Voest EE. Genomics- and transcriptomics-based patient selection for cancer treatment with immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(11):1490–5. - DOI
    1. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. - DOI
    1. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. - DOI
    1. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in Lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104. - DOI

Substances

LinkOut - more resources